MedTrace Logo

Atherogenic Index of Plasma and Tadalafil Response in Erectile Dysfunction

NCT07479901 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 176

Last updated 2026-09-01

No results posted yet for this study

Summary

This prospective single-center observational cohort study examined whether baseline atherogenic index of plasma (AIP), calculated from routine triglyceride and high-density lipoprotein cholesterol measurements, was associated with response to once-daily tadalafil in men aged 40 years or older with erectile dysfunction. Tadalafil 5 mg once daily was prescribed as part of routine clinical care, independently of study participation, and participants were prospectively followed for 12 weeks. Erectile function was assessed using the six-item International Index of Erectile Function-Erectile Function domain (IIEF-EF) at baseline and Week 12. Treatment response was defined as an increase of at least 4 points in the IIEF-EF score from baseline. All participants received tadalafil, and there was no untreated or placebo comparator; therefore, the study evaluated the association between baseline AIP and observed outcome during tadalafil treatment.

Conditions

Interventions

DRUG

tadalafil

Tadalafil 5 mg was prescribed orally once daily for 12 weeks as part of routine clinical care, independently of study participation.

Sponsors & Collaborators

  • Taksim Egitim ve Arastirma Hastanesi

    lead OTHER_GOV

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-21
Primary Completion
2026-02-21
Completion
2026-02-21
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07479901 on ClinicalTrials.gov